The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer

被引:0
作者
Maj-Britt Jensen
Anne-Vibeke Lænkholm
Torsten O. Nielsen
Jens Ole Eriksen
Pernille Wehn
Tressa Hood
Namratha Ram
Wesley Buckingham
Sean Ferree
Bent Ejlertsen
机构
[1] Copenhagen University Hospital,Danish Breast Cancer Cooperative Group, Rigshospitalet
[2] Zealand University Hospital,Department of Surgical Pathology
[3] University of British Columbia,Department of Pathology and Laboratory Medicine
[4] NanoString Technologies,Danish Breast Cancer Cooperative Group, Department of Oncology, Rigshospitalet
[5] Inc,undefined
[6] Copenhagen University Hospital,undefined
来源
Breast Cancer Research | / 20卷
关键词
Breast neoplasms; Adjuvant chemotherapy; Cyclophosphamide; CMF; PAM50;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 118 条
[1]  
Bonadonna G(1976)Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 405-410
[2]  
Brusamolino E(2010)Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer Cancer 116 2081-2089
[3]  
Valagussa P(1992)Adjuvant chemotherapy of breast cancer. NIH consensus development conference, July 14–16, 1980 Cancer Treat Res 60 371-374
[4]  
Rossi A(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717
[5]  
Brugnatelli L(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 432-444
[6]  
Brambilla C(2000)Molecular portraits of human breast tumours Nature 406 747-752
[7]  
Ejlertsen B(2012)Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial Clin Cancer Res 18 2402-2412
[8]  
Mouridsen HT(2010)Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 55-65
[9]  
Jensen MB(2015)Development and verification of the PAM50-based Prosigna breast cancer gene signature assay BMC Med Genet 8 54-345
[10]  
Andersen J(2014)Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone Ann Oncol 25 339-953